U.S. Markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.1862%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.3841%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.1918%)
     
  • BTC-USD

    19,334.22
    -138.50 (-0.71%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine

·1 min read
  • Amyris Inc (NASDAQ: AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ: IBRX) to commercialize a next-gen COVID-19 vaccine.

  • The parties have signed a binding term sheet, and a definitive agreement is in process and is expected to be executed within the next month.

  • ImmunityBio will be responsible for manufacturing the vaccine once human trials are completed in South Africa.

  • Amyris will contribute its RNA technology licensed from the Infectious Disease Research Institute (IDRI).

  • Amyris will also provide sustainable squalene, an organic compound used to produce the vaccine.

  • Upon completion of human trials, the joint venture's goal is to deliver one billion doses of the new vaccine in 2022.

  • Price Action: AMRS shares are down 3.94% at $13.53, and IBRX shares are up 2.14% at $8.62 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.